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Given the high co-occurrence between alcohol use disorder (AUD)
and mental health conditions (MHCs), and the increased morbidity
associated with the presence of co-occurring disorders, it is important
that co-occurring disorders be identified and both disorders addressed
in integrated treatment. Tremendous heterogeneity exists among
individuals with co-occurring conditions, and factors related to both
AUD and MHCs, including symptom type and acuity, illness severity, the
chronicity of symptoms, and recovery capital, should be considered
when recommending treatment interventions. This article reviews
the prevalence of co-occurring AUD and MHCs, screening tools to
identify individuals with symptoms of AUD and MHCs, and subsequent
assessment of co-occurring disorders.Types of integrated treatment and
current challenges to integrate treatment for co-occurring disorders
effectively are reviewed. Innovative uses of technology to improve
education on co-occurring disorders and treatment delivery are also
discussed. Systemic challenges exist to providing integrated treatment
in all treatment settings, and continued research is needed to determine
ways to improve access to treatment.
KEY WORDS: alcohol use disorder; integrated treatment; mental health
condition; screening; treatment setting

Introduction
Given the high co-occurrence between alcohol use disorder (AUD)
and mental health conditions (MHCs),1 and the increased morbidity
associated with the presence of co-occurring disorders,2 it is important
to identify the co-occurring disorders and to address both disorders
in treatment to improve treatment outcome. Treatment that addresses
both disorders concurrently with the same provider or treatment team
is called integrated treatment. As integrated treatments continue to be
developed, evaluated, and implemented, the heterogeneity associated
with co-occurring AUD and MHCs needs to be acknowledged,
since it can affect individual functioning and prognosis. Factors that
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contribute to heterogeneity among individuals
with co-occurring AUD and MHCs include acuity
of symptoms, severity of illness, chronicity of
symptoms, co-occurring drug use, physical health,
cognitive impairment, and recovery capital (Table 1).
Recovery capital is a newer dimension to consider,
which includes the amount of available resources a
person has to support stabilization of AUD and the
transition into recovery.3
Table 1 Factors That Affect Functioning and Prognosis for Individuals
With Co-Occurring AUD and MHCs
Factor

Examples

Acuity of
Symptoms

• Symptoms of alcohol withdrawal that require
urgent medical management

• Active suicidal ideation that requires inpatient
psychiatric admission

• Current symptoms of disorder only
• Lifetime history of disorder
Severity of
Illness

• Severe AUD
• Serious mental illness: schizophrenia, bipolar
disorder, treatment-resistant major depressive
disorder, or anxiety associated with agoraphobia

Chronicity of
Symptoms

• Recent onset of symptoms
• Chronic symptoms with minimal periods of

Co-Occurring
Drug Use

• Injection drug use
• Substances (e.g., cocaine) associated with

recovery

psychiatric symptoms (e.g., anxiety and
psychosis)
Physical
Health

• Malnutrition or liver cirrhosis related to chronic

Cognitive
Impairment

• Substance related
• Low IQ
• Head trauma

Recovery
Capital

•
•
•
•
•

alcohol use

• Physical disability
• Infectious disease: HIV or hepatitis C
• Pregnancy and family planning

Employment
Education
Finances
Living situation
Social networks

This article provides a background on the
prevalence of AUD and co-occurring MHCs,
discusses screening tools to identify individuals with
symptoms of problematic alcohol use and an MHC,
and discusses subsequent assessment of co-occurring
disorders. Patient placement considerations and
types of integrated treatment are also covered. The
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article concludes with a discussion of the challenges
of integrating treatment for co-occurring disorders
effectively and the recent innovations in education
and treatment delivery that address some of these
challenges.

Background
Over the past 30 years, there has been increasing
awareness that AUD frequently co-occurs with
MHCs. The high rate of co-occurring AUD
and MHCs is not surprising, since research has
demonstrated that young people with a history of
an MHC, when compared to peers with no MHC
history, are at increased risk to initiate alcohol use,
transition to regular use, and subsequently develop
AUD.4 Furthermore, co-occurrence begins to emerge
early. One study found that adolescents with an
MHC had onset of alcohol use, regular alcohol use,
and AUD at median ages of 12.2 years, 13.8 years,
and 14.3 years, respectively.4
Individuals with AUD, when compared to
individuals with MHCs, have a higher prevalence
of co-occurring disorders. More specifically, among
adults in the United States in 2017, an estimated
14.1 million had AUD, and 46.6 million had an
MHC.1 Within these two groups, 5.9 million adults
had current, co-occurring AUD and MHCs, which
represents 41.8% of individuals with current AUD
and 12.7% of individuals with a current MHC. In
adults, AUD has been associated with an increased
lifetime risk for major depressive disorder (adjusted
OR of 1.3), anxiety disorder (adjusted OR of 1.3),
and bipolar I disorder (adjusted OR of 2.0), as
well as with antisocial and borderline personality
disorders (adjusted ORs of 1.9 and 2.0, respectively).5
For MHCs, a history of childhood attention
deficit hyperactivity disorder, oppositional defiant
disorder, or conduct disorder has been associated
with an increased risk for developing AUD,6 and
bipolar I disorder, antisocial personality disorder,
and psychotic spectrum illness have been associated
with substantially higher rates of lifetime and
current AUD.7,8
Co-occurring AUD and MHCs have been
associated with poorer outcomes, such as increased
rate of relapse,9 use of psychiatric services, and use
of emergency services,2 when compared to each
disorder separately. Although treatment interventions

have been developed specifically for individuals
with AUD, most treatment is provided in clinical
settings that treat both AUD and other drug use
disorders, hereafter called substance use disorder
(SUD) treatment.
Until the increased recognition of co-occurring
disorders in the 1980s and 1990s, patients who
presented for SUD or mental health treatment often
were not evaluated for a co-occurring disorder, or
their treatment plan did not address the co-occurring
disorder. Since neither disorder is likely to show
sustained improvement if one disorder is treated
without acknowledging the presence or influence
of the co-occurring disorder,10-13 different treatment
approaches were developed to address co-occurrence,
including sequential, parallel, and integrated
treatments. In sequential treatment, one disorder
is assessed and treated before addressing the other
disorder. In parallel treatment, different providers or
treatment teams address each disorder separately. In
integrated treatment, the same provider or treatment
team addresses both disorders concurrently.
If one treatment team provides care, the providers
work in the same setting and coordinate care.
Colocation of treatment and coordinated care helps
providers give patients a consistent message regarding
treatment and recovery.14 Integrated treatment is
considered the standard of care regardless of the
treatment setting (SUD or mental health) a patient
presents to first.15
To support the dissemination of integrated
treatment, the Substance Abuse and Mental Health
Services Administration (SAMHSA) released
the Integrated Treatment for Co-Occurring
Disorders Evidence-Based Practices Kit in 2009,
which remains publicly available.16 Since then,
SAMHSA and the Health Resources and Services
Administration established a Center for Integrated
Health Solutions to support the development of
integrated primary and behavioral health care for
MHCs, SUD, and physical health conditions such
as hypertension, obesity, and cardiovascular disease.
These efforts are needed, since most individuals
with co-occurring SUD and MHCs do not receive
integrated treatment. For example, in 2017, only
8.3% of adults with an MHC and co-occurring
SUD received mental health and SUD services,
whereas 38.2% received mental health services
only, 4.4% received SUD treatment only, and
49% received no treatment.1

Screening and Assessment
One factor contributing to low rates of integrated
treatment for individuals with co-occurring AUD
and MHCs is poor identification of the presence of
a co-occurring disorder. Like other health conditions
for which routine screening occurs at certain ages
(e.g., breast cancer screening for women beginning
at age 40) or in certain settings (e.g., screening
for hyperlipidemia in primary care settings),
screening for both the presence of AUD and for
other MHCs can be efficiently conducted. This
screening, however, may be rare in practice, especially
among certain subgroups. One review found that
adolescents, individuals from low socioeconomic
backgrounds, and racial/ethnic minorities often
are not identified as having a co-occurring
disorder, despite having both disorders.17 Routine,
standardized screening is necessary to identify
problematic alcohol use and mental health symptoms
and to assess for co-occurring disorders.
Screening for alcohol and other substance use
in the medical setting has become the standard
of care because of the demonstrated efficacy
of screening, brief intervention, and referral to
treatment (SBIRT) in the primary care setting
for reducing problematic alcohol use.18 Over the
past 15 years, emphasis on implementing SBIRT
in other health care settings, such as emergency
departments and inpatient medical settings,
has increased.19 Given the relationship between
AUD and MHCs, these medical settings present
opportunities for incorporating screening for mental
health symptoms with screening for problematic
alcohol use, and further research is needed on how
to do this. Likewise, more research is needed on
the effectiveness of SBIRT in the mental health
treatment setting, since most individuals with
co-occurring MHCs and AUD receive mental health
treatment only. Table 2 lists representative examples
of screening tools that assess for problematic alcohol
use and other substance use. Screening for symptoms
of an MHC in an SUD treatment setting is also
necessary. Table 3 includes examples of screening
tools for MHCs.
In addition to detecting the presence or absence
of co-occurring AUD or MHCs, understanding the
nature, scope, chronicity, and effect of the primary
disorder and the co-occurring ones is critically
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Table 2 AUD and SUD Screening and Assessment Tools for the Primary Care Setting
Tool

Description

AUD
Alcohol Screening and Brief
Intervention for Youth: A
Practitioner’s Guide20

•
•
•
•

Alcohol Use Disorders
Identification Test (AUDIT)21

• Clinician- or patient-administered screening
• Developed for adults
• Ten questions about alcohol use, three questions in abbreviated version (AUDIT-C)

Clinician-administered screening
Developed for youth ages 9 to 18
Two questions about patient and peer alcohol use
Developmentally specific questions for patients in elementary school, middle school, and high school

AUD and SUD
Screening to Brief Intervention
(S2BI)22
Brief Screener for Tobacco,
Alcohol, and Other Drugs
(BSTAD)23
Tobacco, Alcohol, Prescription
Medication, and Other
Substance Use (TAPS)24

•
•
•
•

Clinician- or patient-administered screening
Developed for adolescents
Three initial questions about tobacco, alcohol, and marijuana use in the past year
Four additional questions about other types of drugs if adolescent replied yes to any of the three
initial questions
• For S2BI, four choices for frequency of use over the past year
• For BSTAD, number of days of use over the past year

• Clinician- or patient-administered screening and assessment
• Developed for adults
• Four initial questions about tobacco, alcohol, illicit drugs, and nonmedical use of prescription drugs in
the past year

• Additional questions to assess risk level if patient replied yes to initial questions
National Institute on Drug Abuse
(NIDA) Quick Screen25

• Clinician-administered screening and assessment
• Developed for adults
• Four initial questions about frequency of tobacco, alcohol, illicit drug, and nonmedical prescription drug use
in the past year

• Clinician intervention guided by patient response
•
•
•
•

Clinician-administered screening and assessment
Developed for adults
Questions about lifetime and past 3-month use of tobacco, alcohol, and seven other drugs
Assessment of frequency, desire to use, and associated substance use problems if patient endorsed
substance use in the past 3 months
• Questions about injection drug use, concern from friends or relatives, and difficulty with decreasing
substance use if patient endorsed lifetime substance use

Alcohol, Smoking and
Substance Involvement
Screening Test (ASSIST)26

Table 3 MHC Screening Tools
Screening Tool

Description

Pediatric Symptom
Checklist (PSC)27

• Parent- or child-administered screening for emotional or behavioral problems
• Developed for children and adolescents ages 6 to 16 seen in primary care
• Seventeen or 35 questions that assess psychosocial functioning

Patient Health
Questionnaire (PHQ-9)28

• Patient-administered screening for depression
• Developed for adults seen in primary care
• Nine questions

Generalized Anxiety
Disorder (GAD-7)29

• Patient-administered screening for generalized anxiety disorder
• Developed for adults seen in primary care
• Seven questions

Mental Health Screening
Form III30

• Clinician- or patient-administered screening to identify psychiatric co-occurrence
• Developed for adults receiving treatment for SUD
• Eighteen questions
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important for formulating an effective treatment
and recovery plan. Typically, this process is called
the assessment, in contradistinction to the initial
screening. Longer comprehensive assessment tools
for SUD that also assess for problems related to an
MHC have been used in clinical trials and in the
community. These tools include the semistructured
Addiction Severity Index (ASI),31 the Global
Appraisal of Individual Needs (GAIN),32 and
the American Society of Addiction Medicine
(ASAM) Criteria.33 The psychiatric scales from the
ASI have been shown to be an effective tool for
identifying individuals with a co-occurring MHC,
but further assessment is needed to determine
which co-occurring disorder is present.34 The
GAIN assesses for symptoms of specific psychiatric
disorders, including internalizing disorders such
as depression, anxiety, trauma, and suicide, as well
as externalizing disorders such as attention deficit
hyperactivity disorder and conduct disorder.32 The
ASAM Criteria was designed to help clinicians
determine the recommended treatment setting and
level of care for patients with SUD, but it includes
a brief mental health symptom assessment that can
be used to identify acute psychiatric safety concerns
and symptoms that need further assessment.33
One challenge to screening and assessing for
co-occurring MHCs in individuals with AUD
is that problematic alcohol use is associated with
changes in mood, sleep, concentration, and anxiety.
Initially, it may be unclear if someone suffers
from a co-occurring MHC that is independent
of alcohol or drug use and that warrants focused
attention, or if symptoms or the apparent disorder
will dissipate with alcohol or drug abstinence.
To address this challenge, the fifth edition of
the Diagnostic and Statistical Manual of Mental
Disorders (DSM) includes the diagnosis “alcoholinduced mental disorders” to describe symptoms
of a temporary MHC only observed during severe
alcohol intoxication or during withdrawal from
alcohol.35 Therefore, comprehensive screening
and assessment of co-occurring MHCs should
not be done when an individual is intoxicated or
is experiencing withdrawal symptoms. Generally,
in addition to screening for symptoms of an
MHC during an individual’s initial engagement
in treatment, clinicians should reassess mental
health symptoms later during treatment to confirm

the diagnosis and severity of the MHC and to plan
for treatment.
Although there should be no “wrong door” for
treatment when an individual with AUD and a
co-occurring MHC presents for care, until integrated
treatment of both disorders is more commonplace,
clinicians need to consider the severity and effects
of each disorder when recommending treatment
settings. The quadrant model is a tool that can be
used to help clinicians make these recommendations.
The quadrant model has four treatment categories
based on the severity of the SUD and MHC: the
primary health care setting, the SUD setting, the
mental health system, and specialized co-occurring
disorder programs.36 This model has been adopted
by national addiction and mental health treatment
administrators,37 has been validated as effective at
categorizing patients with co-occurring disorders,
and has been associated with appropriate service
utilization.38
The quadrant model can also help clinicians
assess whether a patient would benefit from referral
to a different treatment program to expedite
symptom stabilization and maximize treatment
efficacy. However, the quadrant model assumes
comprehensive screening and assessment of substance
use and mental health symptoms. Thus, continued
efforts are needed to improve screening for both
disorders to facilitate a thorough assessment and
subsequent referral to appropriate treatment. Most
patients and families do not know or understand
the differences between treatment settings, so more
research is needed on how to facilitate treatment
referrals so patients remain engaged in care.

Types of Integrated Treatment
Regardless of the treatment setting, behavioral
therapy, pharmacotherapy, and recovery support in
the patient’s community should be considered in
treatment plans for patients with co-occurring AUD
and MHCs. Because of the heterogeneity among
co-occurring AUD and MHCs, individualized
treatment plans should account for the severity of
each disorder and for patient preference regarding
interventions. Also, although not typically assessed,
the amount of available resources a person has for
stabilization and recovery needs to be included
in the assessment to inform the treatment plan.
Integrating Treatment | e5

These resources often are called “recovery capital,”
a dimension3 that recently developed tools can
assess.39,40 Two clinically identical patients can
have different levels of recovery capital in terms of
employment, education, finances, living situation,
and social networks, all of which can affect clinical
interventions and, ultimately, the likelihood of
remission and long-term recovery.

Behavioral therapy
Behavioral therapies, such as motivational
enhancement therapy, cognitive behavioral therapy,
contingency management, and 12-step facilitation,
are the standard of care for individuals with AUD
and are a key part of a treatment plan for individuals
with co-occurring AUD and MHCs.41 As such,
behavioral therapy for AUD, which is commonly
motivational enhancement therapy or cognitive
behavioral therapy, is provided to all participants
in most randomized controlled trials that evaluate
pharmacotherapy for individuals with AUD and
an MHC. Although less commonly discussed,
AUD-focused therapies delivered to individuals
with MHCs may need to be adapted to account
for the MHC. For example, Levin and colleagues
modified the delivery of cognitive behavioral therapy
for SUD when working with individuals who
had co-occurring attention deficit hyperactivity
disorder.42 The researchers allowed in-session time
for completing homework assignments, checked in
with participants after presenting any new paradigm
for understanding drug use behavior, and used visual
diagrams to help with skills training.
Other behavioral therapies designed to address
MHCs, such as cognitive behavioral therapy for
depression or anxiety and dialectical behavioral
therapy for mood dysregulation, can be integrated
into the treatment plan for individuals who have
co-occurring disorders. For example, integration
of modules from cognitive behavioral therapy
for individuals with AUD and depression may
include introducing skills to address each disorder
at alternating sessions. Increasingly, co-occurring
disorders are being addressed simultaneously in a
single session. Examples include integrated group
therapy for adults with bipolar disorder and SUD,43
integrated individual cognitive behavioral therapy
for depression and SUD,44 integrated cognitive
behavioral therapy for post-traumatic stress disorder
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and SUD,45 and “seeking safety,” a group therapy for
individuals with a history of trauma and SUD.46
These integrated protocols appear to be promising.
Researchers that conducted a meta-analysis of
studies that combined cognitive behavioral therapy
and motivation interviewing to treat individuals
with depression and AUD found that integrated
treatment, when compared to usual care, was
associated with small but clinically significant
improvements in depressive symptoms and alcohol
use.47 Another review of integrated treatments for
individuals with SUD and trauma experiences also
found that integrated treatment was associated
with improvement in both SUD and symptoms of
post-traumatic stress disorder, but no clear benefit
was found for integrated treatment when it was
compared to nonintegrated treatment.48 Further
research is needed to compare the efficacy, cost,
and patient satisfaction associated with integrated
versus nonintegrated behavioral treatment of
AUD and MHCs.

Pharmacotherapy
Pharmacologic trials for co-occurring AUD and
MHCs have focused primarily on treating the
MHC with a medication that has demonstrated
efficacy for treating the MHC in the absence of
co-occurring AUD.49-51 This type of trial includes,
for example, using an antidepressant medication
to treat an individual who has AUD and major
depressive disorder. On average, these pharmacologic
trials have shown modest improvements in
the MHC, with limited improvement in the
co-occurring AUD.52,53 Likewise, clinical trials that
used medication effective at treating AUD alone
have shown some improvement in the AUD, with
limited improvement in the co-occurring MHC.50,54
Importantly, in the studies that evaluated the
effectiveness of AUD medication for co-occurring
AUD and MHCs, most participants were also
simultaneously receiving medication for the MHC,
which may have affected study outcome.54,55
Pharmacologic trials for co-occurring disorders
have been limited by small sample sizes, which
reflects difficulty recruiting and retaining participants
in these trials. Given these challenges, studies using
registries or electronic medical record databases may
be an alternative for evaluating outcomes associated
with available pharmacologic treatments. For

example, one recent quasi-experimental study used
public databases to examine the effect of medication
treatment for AUD among adults involved in the
criminal justice system.56 These participants had
alcohol dependence (per the DSM-IV classification)
and serious mental illness (i.e., schizophrenia, bipolar
disorder, or major depressive disorder). Although
details on abstinence, heavy-drinking days, and
symptoms of the MHC were not accessible through
the public databases used in this study, the databases
allowed investigators to identify a large sample
(N = 5,743) and use information on functional
outcomes, which served as a proxy for traditional
outcomes used in a randomized controlled trial. In
this study, individuals who received medication for
AUD were less likely at the 1-year follow-up to have
been hospitalized for a psychiatric condition or to
have used the emergency department. They also were
more likely to have adhered to their psychotropic
medication regimen than participants who were not
taking these medications.
The overall literature on pharmacotherapy for
co-occurring AUD and MHCs suggests medication
without other treatment interventions may not
be adequate to stabilize both conditions.52,57
Nonetheless, medication is a treatment option
that should be discussed with patients who have
co-occurring disorders. For more serious mental
illness, specifically bipolar disorder and psychotic
disorders, disorder-specific medication is necessary
for initial stabilization and maintenance.37 For
other MHCs, such as depression and anxiety with
mild to moderate impairment and AUD with mild
impairment, when each disorder is considered
separately, treatment guidelines suggest medication
or therapy as options for first-line treatment,
although medication is more strongly indicated
for individuals who have greater impairment.58-60
More research is needed to determine if medication
should be more strongly indicated for co-occurring
AUD and MHCs causing mild impairment, given
the more complicated course of illness when these
disorders co-occur.

Recovery support in the community
Peer-led mutual help organizations can be another
component of a treatment plan for individuals with
co-occurring AUD and MHCs. Beginning in the
1980s, mutual help organizations for individuals

with SUD and an MHC were formed, including
Dual Recovery Anonymous, Double Trouble in
Recovery, and Dual Diagnosis Anonymous.61 These
groups all follow the 12 phases or traditions of
12-step organizations, but they have modifications
addressing the co-occurring MHC. Relative to
12-step organizations for AUD alone, such as
Alcoholics Anonymous, mutual help groups for
individuals with co-occurring disorders are less
common, and less research exists that evaluates
the relationships among group attendance, mental
health symptoms, and alcohol use. In one study of
individuals with psychotic disorders (schizophrenia
or schizoaffective disorder) and AUD and/or cocaine
use disorder, in which a majority of the participants
were African American, investigators found that
regular attendance at Double Trouble in Recovery
was associated with fewer psychiatric symptoms,
increased rates of abstinence, and greater adherence
to psychiatric medication.62
Because of their greater national presence,
mutual help organizations for AUD or MHCs are
much more accessible than those for co-occurring
disorders. Among the mutual help organizations
for AUD, Alcoholics Anonymous is the largest,
with approximately 61,000 meetings serving
1.3 million members in the United States.63 Also,
Alcoholics Anonymous has been the mutual help
organization most thoroughly evaluated for the effect
of participation, both for individuals with AUD and
for those with co-occurring AUD and an MHC.
A recent systematic review and meta-analysis of
patients with AUD and co-occurring MHCs found
that AUD improved with Alcoholics Anonymous
attendance, and the patients with co-occurring AUD
and an MHC benefited from engagement with
Alcoholics Anonymous as much as patients with no
co-occurring MHC.64
Mutual help organizations for individuals with
MHCs have greatly expanded over the past 30 years
as part of an overall emphasis on including peers
in the recovery process. Whether participation in
these groups provides benefit has been less clear,65
and research in this area has been complicated by
a lack of standardization across groups. Substantial
variability exists regarding services provided by
these groups, which can include telephone support
hotlines, social and recreational activities, and
advocacy, in addition to face-to-face meetings. Also,
research evaluating the efficacy of these groups
Integrating Treatment | e7

has not examined differences between individuals
who have an MHC with a co-occurring AUD and
those with no co-occurring AUD. Further research
is needed to determine the ways individuals with
co-occurring AUD and MHCs might benefit from
participation in a mutual help organization that is
focused on alcohol and other substance use versus a
group focused on symptoms of the MHC.
In addition to in-person peer support, individuals
who have AUD and/or MHCs are increasingly
seeking support through online support groups and
social media.66,67 Research is ongoing to determine
the effectiveness, important characteristics (e.g.,
synchronous, such as chat rooms; asynchronous,
such as forums; and level of monitoring from
moderators), and risks of online peer support.
Because of the heterogeneity associated with
co-occurring AUD and MHCs, people with similar
illness experiences may be geographically far apart,
and online peer support could help them connect.

Comprehensive integrated treatment for
serious mental illness and AUD
Evidence-based practices for integrated treatment
programs for individuals with substantial impairment
and low functioning because of AUD and a serious
mental illness, such as schizophrenia or bipolar
disorder, include incorporating interventions that
match an individual’s stage of readiness for treatment
engagement68 and involve assertive outreach,
motivational interventions, and counseling to build
cognitive and behavioral skills. Evidence-based
practices also include strengthening an individual’s
connection with social supports that encourage
recovery, a comprehensive approach that addresses
AUD and MHCs in all aspects of the program,
including social services, and takes a long-term,
community-based perspective on recovery. Cultural
sensitivity and competence are also crucial aspects of
integrated treatment programs.
One example of a comprehensive integrated
treatment is integrated dual diagnosis treatment,
which incorporates these evidence-based practices
and integrates all components of a treatment
plan, including psychological, pharmacological,
educational, and social interventions.69 Assertive
community training and intensive case management
are two other treatments that have been adapted
for individuals with serious mental illness and
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co-occurring AUD.37 These two treatments both
involve intensive case management, skills training,
and individual counseling.
The research supporting superior efficacy
associated with integrated treatment remains limited.
However, in a systematic review of randomized
controlled trials of long-term integrated psychosocial
interventions for individuals with SUD and serious
mental illness, when the researchers compared
integrated intervention with usual care, they found
no significant differences in participant alcohol or
substance use, functioning, or life satisfaction.70 The
investigators noted that their systematic reviews of
the existing literature were limited by differences
in study design and the outcomes used to evaluate
intervention efficacy, as well as by low rates of subject
retention, longitudinally.

Challenges in Implementing
Integrated Treatment
Although integrated treatment is considered the
standard of care for individuals with co-occurring
AUD and MHCs, implementing it in both SUD
and mental health treatment centers has been
difficult. Some of the implementation challenges
relate to the independent development of the
public mental health and SUD treatment systems,
which have differences in workforce training
(e.g., coursework and clinical rotations), licensure
requirements, and reimbursement.
Training and licensure requirements for providers
delivering the same type of treatment vary among
specialties. For example, behavioral therapies are
commonly delivered by psychologists, social workers,
counselors with primary training in MHCs, or
alcohol and drug counselors. The programs that train
these providers have different accreditation bodies
that oversee the educational requirements during
training. The programs also have different state
licensure requirements. In 2009, the Council for
Accreditation of Counseling and Related Educational
Programs revised its standards to emphasize that
mental health counselors need to have exposure to
coursework specific to substance use.71 When mental
health counseling programs were surveyed in 2013,
69% required this coursework, and 13% offered it as
an elective.72 In contrast, the Council on Social Work

Education has no emphasis on coursework specific to
substance use, and the same survey found only 2% of
master’s degree programs in social work required this
coursework, and only 64% offered it as an elective.
For alcohol and drug counselors, training
traditionally has emphasized clinical rotations,
but more recently it has been shifting toward
incorporating more formalized coursework.73 Unlike
other behavioral therapy providers, alcohol and drug
counselors have no national accreditation system
to guide their training for MHCs, and training
programs are more influenced by state licensure
requirements. Differences in training and licensure
may affect the dissemination and implementation of
newer evidence-based practices, such as integrated
treatments. Standardized training and licensure
requirements could provide a mechanism for
monitoring training, and it could potentially
encourage dissemination of newer practices through
continuing education requirements.
However, requiring that all providers receive
training in both SUD and MHCs does not
guarantee they will receive didactic and clinical
training in both conditions or training in integrated
treatment. Training experiences for these disorders
generally occur separately. In part, separate training
experiences occur because integrated services may
not have been developed to serve as a clinical
training site, and because many educators lack
training and expertise in the management of
co-occurring disorders.
For example, although graduate medical education
for psychiatry requires that trainees be exposed
to addiction psychiatry, concerns have been
raised that the current training does not produce
psychiatrists who are well-prepared to manage SUD,
or co-occurring SUD and MHCs, in practice.74
When training directors of general psychiatry were
surveyed to identify barriers to adequate training
in addiction, the two most commonly identified
barriers were limited faculty and staff with expertise,
and limited faculty and staff time to supervise clinical
experiences.74 This survey also found that in 2017,
only 15% of general psychiatry training programs
had board-certified faculty in addiction psychiatry,
and only 37% of programs had board-certified
faculty in addiction medicine.
Since no formal training paths offer training
in integrated treatment, providers generally need
to pursue training in each field to be prepared

to provide this type of care. Few incentives exist
for pursuing additional training, because within
the SUD and mental health treatment systems,
additional reimbursement is not provided
for delivering integrated treatment services.
Reimbursement inequities also exist for each type
of care. Historically, insurance benefits for mental
health treatment have been greater than the benefits
for substance use treatment.75
The federal Mental Health Parity and Addiction
Equity Act of 2008 was enacted to address this
inequity. Despite the legislation, integrated treatment
delivery is still limited by restrictive diagnostic and
billing criteria that generally assess service eligibility
based on one disorder only.76 Often, the criteria
do not account for the complexity added to either
disorder when a co-occurring disorder is present.
Furthermore, integrated care often requires frequent
communication among providers to effectively
coordinate care, but coordination of care is not a
reimbursable service in fee-for-service insurance
models. SAMHSA continues to work to address
these barriers, and it is possible that as health
care financing transitions from fee-for-service to
population-based care, funding to support integrated
treatment programs may become more flexible.

Innovative Models
One example of an innovative model for
improving education is the Extension for
Community Healthcare Outcomes program for
primary care providers, called Project ECHO
(https://echo.unm.edu). This program uses a
simultaneous video link to connect specialists and
primary care providers in different regions of a state
for regular case-based discussions. In New Mexico,
one focus of Project ECHO has been a weekly
meeting about addictions and psychiatry. A review
of the program suggests that this type of learning
opportunity helped New Mexico increase the
number of physicians who have waivers to prescribe
buprenorphine in underserved areas at a much faster
rate relative to other states in the country.77
Innovative models also have been developed
to address some of the challenges associated with
implementing integrated treatment, particularly
the shortage of providers in the addiction
treatment setting who are trained in both SUD
Integrating Treatment | e9

and MHCs. When two transdiagnostic and not
disorder-specific interventions for MHCs were
evaluated among individuals with AUD and
co-occurring anxiety disorders, the interventions
showed encouraging preliminary results.78,79
Unified protocol therapy is an emotion-focused,
cognitive behavioral therapy treatment that has
been shown to be effective for a range of different
MHCs, including anxiety, depression, and bipolar
disorder. In an 11-week study, 81 individuals
who had AUD and an anxiety disorder were
randomized to 4 conditions, and the group
that received the unified protocol therapy was
the only group to have a significant reduction
in heavy-drinking days when compared to the
other groups.78
Acceptance and commitment therapy is a
mindfulness-based form of behavioral therapy
that has been shown to be effective for anxiety
and depression, as well as for SUD. In a 12-week,
uncontrolled pilot study of acceptance and
commitment therapy, which included 43 veterans
with AUD and post-traumatic stress disorder,
researchers found that 67% of the veterans
completed the protocol.79 Improvements in
alcohol use, anxiety, depression, and quality
of life were also reported. More research
is needed to evaluate the efficacy of these
transdiagnostic interventions for co-occurring
AUD and MHCs. Currently, five clinical trials
registered on clinicaltrials.gov are investigating
these two transdiagnostic interventions for
co-occurring disorders.
Another strategy for addressing implementation
challenges has been to leverage technology to help
providers who have no prior specialized training
deliver cognitive behavioral therapy for anxiety
disorders. For example, in the coordinated anxiety
learning and management (CALM) intervention
for addiction recovery, individuals with SUD
and an anxiety disorder receive a group-based,
computer-assisted, but therapist-directed,
treatment for anxiety disorders that has been
adapted for individuals with co-occurring
disorders. In a randomized controlled trial,
individuals who received the CALM intervention
had less anxiety and less substance use through
6-month follow-up when compared to those who
received the usual care.80
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Future Directions
Although integrated treatment for co-occurring
AUD and MHCs makes intuitive sense, the evidence
base supporting integrated treatment, particularly for
co-occurring anxiety and depression, is less mature.
To address the heterogeneity among individuals with
co-occurring disorders, more research is needed on
the types of services, service providers, and treatment
settings that are best for which groups of individuals.
Also, in the evaluation of a treatment’s efficacy, it
is important to include individual strengths, such
as recovery capital, that may moderate or mediate
response to treatment. Recruiting participants who
have AUD and MHCs for randomized controlled
trials to evaluate the effectiveness of treatment can
be challenging, and increasing measurement-based
practice81 within current treatment structures
could help clinicians determine which patients
are struggling and prompt re-evaluation of
treatment plans.
Furthermore, a limited amount of staff and faculty
with expertise in integrated treatment for individuals
with SUD and MHCs has been identified as a
barrier to improving education and subsequent
delivery of care for co-occurring disorders. Therefore,
it is imperative that educators and policy makers
consider increasing virtual and multidisciplinary
training opportunities that focus on addiction,
MHCs, and integrated treatment. Increasing
multidisciplinary training opportunities includes
streamlining continuing education accreditation so
an educational program developed for one group of
providers can easily be shared with other providers
who could benefit from the same information and
who also need continuing education credits for their
specialty.81
Finally, continued innovation is needed to use
promising technologies, such as computerized
interventions, to treat co-occurring disorders in
settings that have limited expertise. Although
some preliminary projects have evaluated adapting
computerized interventions for MHCs for
delivery in the SUD treatment setting, no trials of
computerized interventions for SUD have been
adapted for delivery in the mental health treatment
setting. Since most individuals with co-occurring
SUD and MHCs receive care in the mental health
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setting, this is an important setting for evaluating
these types of interventions.
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